Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Antisense oligonucleotide-mediated upregulation of Jag1 ameliorates liver disease phenotypes in a mouse model of Alagille syndrome.
Journal: Molecular therapy. Nucleic acids
Published: April 01, 2025
OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides.
Journal: Nucleic acid therapeutics
Published: August 17, 2023
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
Journal: Journal of clinical pharmacology
Published: March 27, 2022
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis.
Journal: British journal of clinical pharmacology
Published: November 01, 2021
Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD.
Journal: Kidney international reports
Published: August 13, 2021
Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
Journal: Nucleic acid therapeutics
Published: April 23, 2021
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 22, 2021
An oral antisense oligonucleotide for PCSK9 inhibition.
Journal: Science translational medicine
Published: October 09, 2020
Immunogenicity Assessment of Inotersen, a 2'-O-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety.
Journal: Nucleic acid therapeutics
Published: August 25, 2020
Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Journal: Nucleic acid therapeutics
Published: April 15, 2020
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: December 20, 2019
Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
Journal: Bioanalysis
Published: October 26, 2019
Last Updated: 09/26/2026